文献速递炎症性肠病消化道肿瘤与早癌

系统综述与Meta分析:炎症性肠病患者使用抗肿瘤坏死因子药物和/或硫嘌呤的淋巴瘤比较风险

Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2020-08-25

该系统综述与Meta分析纳入4项观察性研究共261689例炎症性肠病患者,评估抗TNF药物和/或硫嘌呤相关淋巴瘤风险。与未暴露于抗TNF和硫嘌呤者相比,抗TNF单药、硫嘌呤单药和联合治疗的淋巴瘤合并IRR分别为1.52、2.23和3.71。联合治疗风险高于硫嘌呤或抗TNF单药,抗TNF单药与硫嘌呤单药无显著差异。

要点

  • 联合治疗淋巴瘤风险高于硫嘌呤单药(IRR 1.70)和抗TNF单药(IRR 2.49)。
  • 抗TNF单药与硫嘌呤单药淋巴瘤风险无显著差异(IRR 0.72,95%CI 0.48-1.07)。
  • 抗TNF单药、硫嘌呤单药和联合治疗均较未暴露者淋巴瘤风险升高。

核心结论

  • 炎症性肠病患者接受抗TNF药物单用或联合硫嘌呤治疗时淋巴瘤风险升高。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、EMBASE和Cochrane Library,纳入4项观察性研究共261689例炎症性肠病患者。

主要发现

  • 与未暴露于抗TNF和硫嘌呤者相比,抗TNF单药、硫嘌呤单药和联合治疗的淋巴瘤合并IRR(每1000患者年)分别为1.52(95%CI 1.06-2.19;P=0.023)、2.23(95%CI 1.79-2.79;P<0.001)和3.71(95%CI 2.30-6.00;P≤0.01)。
  • 联合治疗淋巴瘤风险高于硫嘌呤单药(合并IRR 1.70,95%CI 1.03-2.81;P=0.039)和抗TNF单药(合并IRR 2.49,95%CI 1.39-4.47;P=0.002)。
  • 抗TNF单药与硫嘌呤单药的淋巴瘤风险无显著差异(合并IRR 0.72,95%CI 0.48-1.07;P=0.107)。
  • 所有观察性研究经Newcastle-Ottawa量表评价均为高质量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The risk of lymphoma in patients with inflammatory bowel disease (IBD) treated with anti-TNF agents remains unclear. AIM: To assess the comparative risk of lymphoma with anti-TNF agents and/or thiopurines in IBD METHODS: We searched PubMed, EMBASE and Cochrane Library to identify studies that evaluated lymphoproliferative disorders associated with anti-TNF agents with or without thiopurines. The risk of lymphoma was assessed through four comparator groups: combination therapy (anti-TNF plus thiopurine), anti-TNF monotherapy, thiopurine monotherapy and control group. Pooled incidence rate ratios (IRR) were estimated through Poisson-normal models. RESULTS: Four observational studies comprising 261 689 patients were included. As compared with patients unexposed to anti-TNF and thiopurines, those exposed to anti-TNF monotherapy, thiopurine monotherapy or combination therapy had pooled IRR (per 1000 patient-years) of lymphoma of 1.52 (95% CI: 1.06-2.19; P = 0.023), 2.23 (95% CI: 1.79-2.79; P < 0.001) and 3.71 (95% CI: 2.30-6.00; P ≤ 0.01), respectively. The risk of lymphoma associated with combination therapy was higher than with thiopurines or anti-TNF alone with pooled IRR of 1.70 (95% CI: 1.03-2.81; P = 0.039) and 2.49 (95% CI: 1.39-4.47; P = 0.002), respectively. The risk did not differ between anti-TNF monotherapy and thiopurine monotherapy with pooled IRR of 0.72 (95% CI: 0.48-1.07; P = 0.107). All observational studies were of high quality according to the Newcastle-Ottawa scale. CONCLUSIONS: There is an increased risk of lymphoma in IBD patients treated with anti-TNF agents, either alone or when combined with thiopurines.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chupin A, Perduca V, Meyer A, et al. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020. PMID: 32840893. doi:10.1111/apt.16050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。